Compare APO & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APO | EW |
|---|---|---|
| Founded | 1990 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.8B | 61.6B |
| IPO Year | 2021 | 1999 |
| Metric | APO | EW |
|---|---|---|
| Price | $111.18 | $101.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 30 |
| Target Price | ★ $146.76 | $113.83 |
| AVG Volume (30 Days) | 3.4M | ★ 4.4M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.61 |
| Revenue | ★ $32,049,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | N/A | $12.24 |
| Revenue Next Year | $16.57 | $9.84 |
| P/E Ratio | ★ N/A | $64.53 |
| Revenue Growth | ★ 22.73 | 11.55 |
| 52 Week Low | $99.56 | $74.66 |
| 52 Week High | $153.29 | $108.00 |
| Indicator | APO | EW |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 60.54 |
| Support Level | $101.77 | $82.21 |
| Resistance Level | $114.70 | N/A |
| Average True Range (ATR) | 4.63 | 2.98 |
| MACD | -0.55 | -0.16 |
| Stochastic Oscillator | 6.32 | 61.41 |
Apollo is one of the world's largest alternative asset managers, with $1.047 trillion in total assets under management, or AUM, including $858.0 billion in fee-earning assets, at the end of June 2026. The company has two core operating segments: asset management and retirement services. Apollo operates with scale in most of its major asset management endeavors—private equity (with an estimated $137.2 billion in total AUM and $76.3 billion in fee-earning AUM), real estate/real assets ($60.8 billion/$27.6 billion), and credit ($849.3 billion/$754.1 billion). Apollo has a distribution profile that is likely not too far off from the industry averages—with 84% of its assets held by institutional investors and 16% by high-net-worth clients.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.